Do you want to read an article? Please log in or register.
Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis
Pediatr Pulmonol.
Kirkham HS, Staskon F, Hira N, McLane D, Kilgore KM, Parente A, Kim S, Sawicki GS
doi: 10.1002/ppul.23978.
Pulmonary Fibrosis
Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients
Pediatr Pulmonol.
Bruch BA, Singh SB, Ramsey LJ, Starner TD
doi: 10.1002/ppul.24024.
RECOMMENDED
Bronchi
Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis.
Lommatzsch ST
doi: 10.1177/1753466620905272.
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results
Swiss Med Wkly.
Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C
doi: 10.4414/smw.2018.14593.
RECOMMENDED
Pulmonary Fibrosis
The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
Havermans T, Houben J, Vermeulen F, Boon M, Proesmans M, Lorent N, de Soir E, Vos R, Dupont L
doi: 10.1016/j.jcf.2020.07.022.
Pulmonary Fibrosis
SILDENAFIL IMPROVES VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS
Am J Physiol Heart Circ Physiol.
Rodriguez Miguelez P, Seigler N, Tucker MA, Csanyi G, McKie KT, Forseen C, Harris RA
doi: 10.1152/ajpheart.00301.2018.
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
Fungal and Bacterial Diversity of Airway Microbiota in Adults with Cystic Fibrosis: Concordance Between Conventional Methods and Ultra-Deep Sequencing, and Their Practical use in the Clinical Laboratory
Mycopathologia.
Botterel F, Angebault C, Cabaret O, Stressmann FA, Costa JM, Wallet F, Wallaert B, Bruce K, Delhaes L
doi: 10.1007/s11046-017-0185-x.
Pulmonary Fibrosis
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
N Engl J Med.
Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS
doi: 10.1056/